Track market-moving stories before they get noisy

Abbott Laboratories maintains a highly diversified healthcare business spanning medical technology, diagnostics, and nutrition. UnitedHealth Group dominates the insurance and healthcare services landscape through its massive scale and integrated Optum division.

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1
Building on its leadership in colorectal cancer screening with the Cologuard® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring

, /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain. Abbott (NYSE: ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease (MRD) test achieved a 30-percent absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery, compared with the whole-exome sequencing (WES) Oncodetect test, using a single post-surgery blood draw.1

For more than 12 years, Abbott's cancer diagnostics business has helped expand access to colorectal cancer screening through Cologuard®. Together with Oncodetect, these innovations reflect Abbott's connected approach to cancer care, from early detection to monitoring for recurrence after treatment.

Conducted in collaboration with Dr. Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East in Japan, Beta-CORRECT is the first clinical validation study of the WGS Oncodetect test in patients with stage II, III and resectable stage IV colorectal cancer. The test tracks up to 5,000 DNA variants unique to each patient's tumor, expanding opportunities to detect residual disease when very little cancer DNA is present.1 The study analyzed post-surgical samples from 279 patients, predominantly with stage II and III colorectal cancer.1

Key findings from Beta-CORRECT:

Improved sensitivity: A single blood test taken approximately one month after surgery using the WGS test achieved 72.2% sensitivity for recurrence within two years, compared with 42.2% for the WES test, a 30-percent absolute improvement.1
Additional ctDNA detection: Among 157 patients tested post-surgery with both tests, the WGS test detected ctDNA in all 29 patients in whom the WES test identified, plus 15 additional patients. All additional detections were at levels below 20 parts per million (ppm), including 14 that were below 10 ppm.1
Strong prognostic value: Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence than ctDNA-negative patients. Two-year disease-free survival rates were 36.2% versus 92.3%, respectively.1
Stage II findings: Patients with detectable post-surgical ctDNA had approximately 31-fold higher recurrence risk compared to those who were ctDNA negative. Only 2.8% of stage II patients with undetectable ctDNA experienced recurrence within two years.2

"Beta-CORRECT adds important clinical evidence supporting the prognostic value of highly sensitive MRD testing in colorectal cancer," said Dr. Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the Beta-CORRECT study. "The ability to identify additional patients with detectable ctDNA after surgery may help refine recurrence risk assessment beyond traditional clinical factors. Continued research will help determine how these findings can best inform patient management."

"These findings reinforce why sensitivity matters in MRD testing, particularly after surgery when ctDNA can be difficult to detect," said Dr. Rick Baehner, divisional vice president, chief medical officer, precision oncology, Abbott's cancer diagnostics business. "By identifying additional patients with residual disease, we can provide physicians with important molecular information about recurrence risk at a critical point in care."

Detecting ctDNA after surgery was the strongest predictor of cancer recurrence among the factors studied, providing important information about a patient's risk beyond traditional clinical measures. Additional patient follow-up and longitudinal data from subsequent testing time points are expected to provide further insights into the relationship between MRD, adjuvant therapy and recurrence risk over time.

The findings were presented at ESMO 2026 in poster 4426P, Validation of the ultrasensitive tumor-informed WGS MAESTRO MRD assay in β-CORRECT.

About the Oncodetect® test
The next-generation Oncodetect® test is a whole-genome sequencing-based, tumor-informed molecular residual disease (MRD) test designed to provide a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. The test analyzes circulating tumor DNA (ctDNA) shed into the bloodstream by tumors, offering insights into changes in ctDNA levels over time. This quantitative assessment of ctDNA (measured as MTM/mL) helps healthcare providers better understand a patient's MRD status and make informed treatment decisions.  

The Oncodetect® test was developed, and its performance characteristics determined by Genomic Health, Inc. Performance characteristics may not apply in tumor types not included in this test's clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Genomic Health Inc. The Genomic Health Inc. lab performing this test is certified under CLIA regulations and qualified to perform high-complexity clinical laboratory testing. 

About Abbott: 
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, and on LinkedIn, Facebook, Instagram, X and YouTube. 

Hashimoto, T. et al. Validation of the ultrasensitive tumor-informed WGS MAESTRO MRD assay in β-CORRECT. Poster 4426P presented at ESMO 2026; October 23-27, 2026; Madrid, Spain.
Data on File – Additional Beta-CORRECT WGS analysis performed. October 2026.

SOURCE Abbott

Key Takeaways Abbott plans to spin off its $8.5B Nutrition business by 2027 to sharpen its portfolio focus.Abbott now expects 6% comparable sales growth in 2026 amid diabetes and electrophysiology pressures.Abbott sees diabetes growth in the low-to-mid-single digits, while new product launches offer opportunities.
Abbott Laboratories (ABT - Free Report) used its third-quarter 2026 earnings call to outline a major portfolio restructuring, announcing plans to separate its Nutrition business into an independent publicly traded company.

Management also addressed reduced revenue growth expectations, competitive pressures in diabetes care and upcoming product launches. The discussion emphasized long-term portfolio positioning alongside near-term execution challenges.

ABT Outlines Nutrition Separation StrategyChairman and CEO Robert Ford said the planned separation reflects increasingly different investment requirements, customer bases and growth profiles across Abbott's businesses. Nutrition has become more influenced by consumer preferences, wellness trends and retail execution.

The proposed company generates approximately $8.5 billion in annual sales and includes brands such as Similac, Ensure and PediaSure. Daniel Salvadori will lead the independent business.

CFO Philip Boudreau expects the transaction to be completed by the end of 2027, subject to approvals. Excluding Nutrition's current financial profile, Abbott expects sales growth to accelerate by 50-100 basis points and operating margin to increase approximately 100 basis points.

Abbott Revises Revenue Growth ExpectationsAbbott now projects approximately 6% comparable sales growth for 2026. Adjusted earnings guidance was narrowed to $5.50-$5.55 per share, while fourth-quarter adjusted EPS is projected at $1.62-$1.67.

ABT’s quarterly adjusted EPS of $1.42 missed the Zacks Consensus Estimate of $1.43. Third-quarter revenues came in at $13.01 billion, exceeding the Zacks Consensus Estimate of $12.97 billion.

During questioning from Wells Fargo, Ford attributed the revised revenue outlook primarily to electrophysiology and diabetes care. He described the pressures as temporary rather than permanent changes in underlying growth potential.

ABT Sees Electrophysiology Launch MomentumElectrophysiology delivered 15.5% comparable growth, supported by adoption of the Volt pulsed field ablation catheter. Ford highlighted accelerating U.S. demand following its full market release in August.

However, weaker left atrial appendage closure demand has offset some ablation momentum. Ford expects approximately 20% electrophysiology growth in the fourth quarter compared with an earlier expectation near 25%.

Abbott anticipates additional momentum from TactiFlex Duo and Volt's planned Japanese launch. Ford also expects the newer Amulet 360 device to help address existing market challenges.

Abbott Faces Diabetes Pricing and Coverage PressuresFord acknowledged that continuous glucose monitoring growth faces greater international pricing competition and slower penetration among patients with type 2 diabetes without broader reimbursement coverage.

Management expects diabetes growth in the low-to-mid-single-digit range over the next several quarters. Abbott plans selective international pricing adjustments while pursuing longer-term customer contracts and protecting market share.

During Citigroup's questioning, Ford declined to forecast when Medicare reimbursement might expand to non-insulin-using type 2 patients. He emphasized that such an expansion is not currently factored into expectations. Libre Duo's planned December launch and improved U.S. formulary coverage offer additional growth opportunities.

ABT Details Cancer Diagnostics OpportunitiesCancer Diagnostics posted 13.8% comparable sales growth, supported by Cologuard and precision oncology activities.

Responding to Jefferies, Ford explained that a July cybersecurity incident disrupted customer connectivity and temporarily reduced growth by approximately one percentage point. He reported recovery after affected systems resumed operations.

Ford also highlighted the recently introduced SimpleScreen blood-based colorectal cancer test. While acknowledging its broader screening potential, he maintained that stool-based testing offers stronger early-detection performance. Management continues advancing personalized cancer diagnostics and integration efforts following the Exact Sciences acquisition.

Abbott Maintains Investment and Capital FlexibilityFord said research and development spending will exceed $3 billion in 2026, with further investment planned for 2027. Priorities include leadless pacing, structural heart technologies, intravascular lithotripsy and additional biosensor applications.

During Citigroup's questions, Ford emphasized that the Nutrition separation would not restrict Abbott's acquisition strategy. Near-term transactions will primarily involve smaller complementary acquisitions.

Boudreau reported an adjusted gross margin of 57.2%, up 140 basis points year over year. Management continues pursuing operational efficiencies alongside innovation investment.

ABT Emphasizes Execution Entering 2027Ford expects sales growth to accelerate in 2027 but indicated that initial guidance will take a more conservative approach. Formal projections will follow in January.

Management's overall message combined confidence in the product pipeline with caution surrounding pricing, reimbursement and launch timing. The Nutrition separation remains central to Abbott's longer-term strategic direction.

Abbott's Zacks Rank and Style ScoresAbbott currently carries a Zacks Rank #2 (Buy), indicating favorable near-term earnings estimate revision characteristics. Its Value, Growth and VGM Scores are C, with a Momentum Score of D. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

These scores indicate moderate value and growth characteristics but weaker price momentum. The combination offers a mixed assessment despite the favorable Zacks Rank. The company's ranking may change as analysts revise earnings estimates following the third-quarter results.

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItAbbott Laboratories NYSE: ABT reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders.

Chairman and Chief Executive Officer Robert Ford said the planned separation follows a strategic review and is intended to give both businesses greater operational focus. The company expects to complete the transaction by the end of next year, subject to required approvals.

Get Abbott Laboratories alerts:

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetThe nutrition company is expected to have about $8.5 billion in annual sales, 16,000 employees and 14 manufacturing sites. Its portfolio will include Similac, PediaSure, Ensure, Glucerna and Pedialyte. Ford said Abbott expects the business to qualify for inclusion in the S&P 500 based on its scale and financial profile.

Daniel Salvadori, Abbott’s executive vice president and group president of Established Pharmaceuticals and Nutrition Products, is slated to become chief executive officer of the new company.

Nutrition Separation and Financial Structure AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?Ford said the nutrition market has increasingly been influenced by consumer preferences, wellness trends and retail execution, rather than being shaped primarily by healthcare professionals. He said an independent company could more effectively invest in sales and marketing, innovation, and potentially tuck-in acquisitions as demand for healthier nutrition products grows.

Abbott said it selected a spinoff rather than a sale after determining that the separation offered a better path for shareholder value creation. Ford said a sale could involve tax implications and a timeline less fully within Abbott’s control.

Chief Financial Officer Phil Boudreau said Abbott shareholders will own shares in both Abbott and the new nutrition company following the distribution. The final share distribution ratio will be disclosed before the separation.

The new nutrition business is expected to raise debt, with a portion of proceeds to be distributed to Abbott, although the amount of debt and distribution have not yet been determined. Abbott said both companies are expected to maintain strong investment-grade credit ratings and to pay dividends that, in combination, equal Abbott’s dividend at the time of separation.

Boudreau said separation-related expenses will be treated as specified items and excluded from adjusted earnings. Abbott does not expect the separation process to affect the adjusted earnings guidance it plans to provide in January.

Excluding nutrition from Abbott’s current portfolio, the company expects sales growth to accelerate by 50 to 100 basis points. It also expects gross margin as a percentage of sales to rise by more than 200 basis points and operating margin to increase by approximately 100 basis points.

Addressing litigation related to infant formula, Ford said resolving those matters is not a prerequisite to completing the separation. He said Abbott and the new nutrition company would be well capitalized to pursue their growth plans and defend their legal positions. Abbott settled claims from 2,000 claimants in August, Ford said, while continuing to stand behind the safety and efficacy of its products.

Third-Quarter Performance Comparable sales increased 7% in the third quarter, while adjusted EPS of $1.42 was in line with Abbott’s guidance and the consensus estimate, according to Boudreau. Foreign exchange had a 0.4% unfavorable year-over-year effect on sales.

Adjusted gross margin was 57.2% of sales, up 140 basis points from a year earlier. Adjusted operating margin expanded 40 basis points to 23.4%. Adjusted research and development spending was 6.9% of sales, while adjusted selling, general and administrative expense was 26.9% of sales.

Diagnostics: Sales rose 6.5%, supported by 5.5% growth in core laboratory testing and 14% growth in cancer diagnostics. Abbott said it launched its first blood-based colorectal cancer screening test in September, adding to its existing stool-based screening offerings. Nutrition: Sales increased 5%, with pediatric nutrition up 9% and U.S. pediatric sales up 11%. Adult nutrition rose 2%, including 3.5% growth in the United States. Abbott cited WIC contract wins and improving retail consumption trends. The company also launched a Similac ready-to-feed liquid infant formula made with whole milk. Established Pharmaceuticals: Sales increased 8.5%, with broad-based growth across emerging markets and double-digit growth in several countries in Asia, Latin America and the Middle East. Medical Devices: Sales rose 8%, led by double-digit growth in electrophysiology and rhythm management. Continuous glucose monitoring sales rose 8%. Medical Device Pipeline and Near-Term Pressures Ford said electrophysiology growth was in the mid-teens to high teens excluding left atrial appendage, or LAA, products. U.S. growth exceeded 20% excluding LAA, aided by adoption of Abbott’s Volt pulsed field ablation catheter after its full U.S. release in mid-August.

The company received FDA approval for its TactiFlex Duo catheter in September and expects to begin a broad U.S. launch in the fourth quarter. Abbott also received CE Mark approval for its Amulet 360 LAA device and said it intends to bring the technology to the U.S. market.

In rhythm management, sales increased 10% as adoption of the AVEIR leadless pacemaker expanded across single- and dual-chamber applications. In diabetes care, Abbott received FDA approval for Libre Duo, a dual glucose and ketone sensor, and expects a U.S. launch in December.

Ford said full-year sales guidance was reduced to approximately 6% growth, implying fourth-quarter growth of slightly more than 8%. He attributed the change primarily to near-term factors in electrophysiology and diabetes care.

In electrophysiology, Abbott expects LAA market conditions and customer ordering patterns ahead of the Amulet 360 launch to pressure growth in the fourth quarter. The company now expects about 20% growth in electrophysiology during the period, compared with a prior expectation of about 25%.

For diabetes care, Ford said Abbott expects low- to mid-single-digit growth over the next several quarters, reflecting challenges penetrating the type 2 population without broader reimbursement and increased international pricing pressure. He said Abbott plans pricing adjustments intended to protect its market share while securing longer-term contracts.

Outlook Abbott expects foreign exchange to reduce fourth-quarter sales by about 1%. The company forecast fourth-quarter adjusted EPS of $1.62 to $1.67.

Ford said Abbott expects overall sales growth to accelerate in 2027 but plans to take a more conservative initial approach to revenue guidance when it provides formal outlook details in January. He said the company still expects gross-margin expansion, earnings growth, continued R&D investment, strong cash flow and dividend growth.

Abbott also said it has capacity for future acquisitions, though Ford indicated that nearer-term activity would likely focus on tuck-in deals as the company continues integrating Exact Sciences.

About Abbott Laboratories (NYSE:ABT)Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Abbott Laboratories Right Now?Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Abbott Laboratories (ABT) Q3 2026 Earnings Call Transcript

Abbott (ABT - Free Report) reported $13.01 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 14.5%. EPS of $1.42 for the same period compares to $1.30 a year ago.

The reported revenue represents a surprise of +0.3% over the Zacks Consensus Estimate of $12.97 billion. With the consensus EPS estimate being $1.43, the EPS surprise was -0.7%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net sales- Nutrition- U.S.: $958 million compared to the $931.65 million average estimate based on four analysts. The reported number represents a change of +7.9% year over year.Net sales- Nutrition- International: $1.3 billion versus $1.28 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.1% change.Net sales- Diagnostics- U.S.: $1.85 billion versus the four-analyst average estimate of $1.85 billion. The reported number represents a year-over-year change of +109.1%.Net sales- Diagnostics- International: $1.45 billion versus the four-analyst average estimate of $1.44 billion. The reported number represents a year-over-year change of +6.2%.Net sales- Nutrition: $2.26 billion versus the five-analyst average estimate of $2.21 billion. The reported number represents a year-over-year change of +5.1%.Net sales- Diagnostics: $3.31 billion versus $3.29 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +46.7% change.Net sales- Medical Devices- Diabetes Care: $2.19 billion compared to the $2.2 billion average estimate based on five analysts. The reported number represents a change of +6.2% year over year.Net sales- Established Pharmaceuticals: $1.61 billion versus the five-analyst average estimate of $1.61 billion. The reported number represents a year-over-year change of +6.8%.Net sales- Medical Devices- Vascular- Total: $786 million versus $775.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.Net sales- Medical Devices- Neuromodulation- Total: $251 million versus the four-analyst average estimate of $263.09 million. The reported number represents a year-over-year change of -1.2%.Net sales- Medical Devices- Structural Heart- Total: $592 million compared to the $598.89 million average estimate based on four analysts. The reported number represents a change of -6.8% year over year.Net sales- Medical Devices- Heart Failure- Total: $387 million versus $396.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change.View all Key Company Metrics for Abbott here>>>

Shares of Abbott have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals , /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2026.

Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis. Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items. Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1. Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55. In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib). In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk —  the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation. In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease. "Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."

THIRD-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

5,504

958

1,853

—

2,687

International

7,509

1,304

1,452

1,614

3,139

Total reported

13,013

2,262

3,305

1,614

5,826

% Change vs. 3Q25

U.S.

28.0

7.9

109.2

n/a

6.6

International

6.2

3.1

6.2

6.8

7.2

Total reported

14.5

5.1

46.7

6.8

6.9

Total reported excl. foreign exchange impact

14.8

4.9

46.6

8.4

7.4

Comparable sales growth

7.0

4.9

6.4

8.4

7.8

    U.S.

7.9

7.9

8.4

n/a

7.6

    International

6.4

2.8

4.0

8.4

8.0

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

14,994

2,673

4,418

—

7,890

International

21,776

3,750

4,159

4,539

9,328

Total reported

36,770

6,423

8,577

4,539

17,218

% Change vs. 9M25

U.S.

17.7

(4.5)

72.0

n/a

7.1

International

8.2

1.1

6.3

9.3

11.7

Total reported

11.9

(1.3)

32.4

9.3

9.6

Total reported excl. foreign exchange impact

10.5

(2.1)

30.8

8.7

7.8

Comparable sales growth

5.2

(2.1)

3.8

8.7

8.2

    U.S.

4.7

(4.5)

4.9

n/a

8.1

    International

5.7

(0.3)

2.4

8.7

8.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

958

577

381

International

1,304

486

818

Total reported

2,262

1,063

1,199

% Change vs. 3Q25

U.S.

7.9

11.0

3.5

International

3.1

6.4

1.3

Total reported

5.1

8.8

2.0

Total reported excl. foreign exchange impact

4.9

8.7

1.8

Comparable sales growth

4.9

8.7

1.8

    U.S.

7.9

11.0

3.5

    International

2.8

6.0

1.0

Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.

Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.

On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Pediatric

Adult

U.S.

2,673

1,613

1,060

International

3,750

1,428

2,322

Total reported

6,423

3,041

3,382

% Change vs. 9M25

U.S.

(4.5)

(4.8)

(4.0)

International

1.1

3.7

(0.5)

Total reported

(1.3)

(1.0)

(1.6)

Total reported excl. foreign exchange impact

(2.1)

(1.6)

(2.6)

Comparable sales growth

(2.1)

(1.6)

(2.6)

    U.S.

(4.5)

(4.8)

(4.0)

    International

(0.3)

2.4

(2.0)

Diagnostics*

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

1,853

389

938

526

International

1,452

1,049

30

373

Total reported

3,305

1,438

968

899

% Change vs. 3Q25

U.S.

109.2

6.3

n/a

1.1

International

6.2

5.1

n/a

1.0

Total reported

46.7

5.4

n/a

1.1

Total reported excl. foreign exchange impact

46.6

5.4

n/a

0.9

Comparable sales growth

6.4

5.4

13.8

0.9

    U.S.

8.4

6.3

13.9

1.1

    International

4.0

5.1

12.1

0.7

Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.

Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.

Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

4,418

1,113

1,921

1,384

International

4,159

3,015

62

1,082

Total reported

8,577

4,128

1,983

2,466

% Change vs. 9M25

U.S.

72.0

6.1

n/a

(8.9)

International

6.3

5.8

n/a

1.9

Total reported

32.4

5.9

n/a

(4.5)

Total reported excl. foreign exchange impact

30.8

4.0

n/a

(5.4)

Comparable sales growth

3.8

4.0

13.5

(5.4)

    U.S.

4.9

6.1

13.5

(8.9)

    International

2.4

3.2

15.0

(0.4)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Established Pharmaceuticals

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,614

1,195

419

Total reported

1,614

1,195

419

% Change vs. 3Q25

U.S.

n/a

n/a

n/a

International

6.8

9.0

1.1

Total reported

6.8

9.0

1.1

Total reported excl. foreign exchange impact

8.4

10.9

1.6

Comparable sales growth

8.4

10.9

1.6

    U.S.

n/a

n/a

n/a

    International

8.4

10.9

1.6

Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

4,539

3,448

1,091

Total reported

4,539

3,448

1,091

% Change vs. 9M25

U.S.

n/a

n/a

n/a

International

9.3

10.5

5.6

Total reported

9.3

10.5

5.6

Total reported excl. foreign exchange impact

8.7

10.4

3.6

Comparable sales growth

8.7

10.4

3.6

    U.S.

n/a

n/a

n/a

    International

8.7

10.4

3.6

Medical Devices

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,687

380

429

303

290

228

185

872

International

3,139

372

444

84

496

364

66

1,313

Total reported

5,826

752

873

387

786

592

251

2,185

% Change vs. 3Q25

U.S.

6.6

9.0

18.1

8.4

3.4

(11.1)

(5.6)

9.4

International

7.2

10.4

12.2

(2.7)

6.7

12.2

13.6

4.2

Total reported

6.9

9.7

15.0

5.8

5.4

1.9

(1.2)

6.2

Total reported excl. foreign exchange impact

7.4

10.0

15.5

6.0

5.7

2.6

(1.1)

6.7

Comparable sales growth

7.8

10.0

15.5

6.0

5.7

6.9

(1.1)

6.7

    U.S.

7.6

9.0

18.1

8.4

3.4

(2.3)

(5.6)

9.4

    International

8.0

11.0

13.1

(1.6)

7.1

13.5

13.9

4.9

Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

7,890

1,096

1,227

908

875

677

551

2,556

International

9,328

1,083

1,295

269

1,491

1,090

203

3,897

Total reported

17,218

2,179

2,522

1,177

2,366

1,767

754

6,453

% Change vs. 9M25

U.S.

7.1

10.4

16.0

10.2

5.2

(10.2)

(2.4)

9.3

International

11.7

13.9

14.5

7.9

8.0

16.1

18.1

10.5

Total reported

9.6

12.1

15.2

9.7

7.0

4.4

2.4

10.0

Total reported excl. foreign exchange impact

7.8

10.6

13.8

8.9

5.2

2.6

1.3

7.7

Comparable sales growth

8.2

10.6

13.8

8.9

5.2

6.5

1.3

7.7

    U.S.

8.1

10.4

16.0

10.2

5.2

(2.3)

(2.4)

9.3

    International

8.3

10.8

11.9

4.6

5.2

12.8

13.5

6.6

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.

Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 411th Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

3Q25

% Change

Net Sales

$13,013

$11,369

14.5

Cost of products sold, excluding amortization expense

5,628

5,075

10.9

Amortization of intangible assets

841

420

n/m

Research and development

920

766

20.1

Selling, general, and administrative

4,266

3,051

39.8

Total Operating Cost and Expenses

11,655

9,312

25.2

Operating Earnings

1,358

2,057

(34.0)

Interest expense, net

297

44

n/m

Net foreign exchange (gain) loss

(6)

(17)

n/m

Other (income) expense, net

(164)

(150)

9.4

Earnings before taxes

1,231

2,180

(43.5)

Taxes on Earnings

311

536

(42.0)

1)

Net Earnings

$920

$1,644

(44.1)

Net Earnings excluding Specified Items, as described below

$2,477

$2,278

8.7

2)

Diluted Earnings per Common Share

$0.53

$0.94

(43.6)

Diluted Earnings per Common Share, excluding Specified Items, as described below

$1.42

$1.30

9.2

2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options

1,738

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

9M25

% Change

Net Sales

$36,770

$32,869

11.9

Cost of products sold, excluding amortization expense

15,843

14,397

10.0

Amortization of intangible assets

1,921

1,260

52.4

Research and development

2,579

2,207

16.9

Selling, general, and administrative

12,031

9,203

30.7

Total Operating Cost and Expenses

32,374

27,067

19.6

Operating Earnings

4,396

5,802

(24.2)

Interest expense, net

664

143

n/m

Net foreign exchange (gain) loss

(15)

(35)

n/m

Other (income) expense, net

(457)

(414)

10.2

Earnings before taxes

4,204

6,108

(31.2)

Taxes on earnings

1,279

1,360

(6.0)

1)

Net Earnings

$2,925

$4,748

(38.4)

Net Earnings excluding Specified Items, as described below

$6,789

$6,410

5.9

2)

Diluted Earnings per Common Share

$1.67

$2.70

(38.1)

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$3.88

$3.65

6.3

2)

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,743

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      841

$      (841)

$        —

Gross Margin

6,544

904

7,448

R&D

920

(28)

892

SG&A

4,266

(761)

3,505

Other (income) expense, net

(164)

4

(160)

Earnings before taxes

1,231

1,689

2,920

Taxes on Earnings

311

132

443

Net Earnings

920

1,557

2,477

Diluted Earnings per Share

$     0.53

$     0.89

$      1.42

Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

3Q25

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      420

$     (420)

$        —

Gross Margin

5,874

470

6,344

R&D

766

(36)

730

SG&A

3,051

(47)

3,004

Other (income) expense, net

(150)

5

(145)

Earnings before taxes

2,180

548

2,728

Taxes on Earnings

536

(86)

450

Net Earnings

1,644

634

2,278

Diluted Earnings per Share

$     0.94

$      0.36

$      1.30

Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$     1,921

$    (1,921)

$        —

Gross Margin

19,006

2,033

21,039

R&D

2,579

(77)

2,502

SG&A

12,031

(1,662)

10,369

Other (income) expense, net

(457)

(30)

(487)

Earnings before taxes

4,204

3,802

8,006

Taxes on Earnings

1,279

(62)

1,217

Net Earnings

2,925

3,864

6,789

Diluted Earnings per Share

$      1.67

$      2.21

$     3.88

Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

9M25

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$    1,260

$   (1,260)

$        —

Gross Margin

17,212

1,396

18,608

R&D

2,207

(83)

2,124

SG&A

9,203

(58)

9,145

Other (income) expense, net

(414)

(31)

(445)

Earnings before taxes

6,108

1,568

7,676

Taxes on Earnings

1,360

(94)

1,266

Net Earnings

4,748

1,662

6,410

Diluted Earnings per Share

$     2.70

$      0.95

$     3.65

Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below: 

3Q26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$     1,231

$       311

25.3 %

1)

Specified items

1,689

132

Excluding specified items

$    2,920

$      443

15.2 %

3Q25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    2,180

$      536

24.6 %

2)

Specified items

548

(86)

Excluding specified items

$    2,728

$      450

16.5 %

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 

9M26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$   4,204

$    1,279

30.4 %

3)

Specified items

3,802

(62)

Excluding specified items

$   8,006

$     1,217

15.2 %

9M25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    6,108

$    1,360

22.3 %

4)

Specified items

1,568

(94)

Excluding specified items

$    7,676

$    1,266

16.5 %

3)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Third Quarter Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

3Q26

3Q25

% Change vs. 3Q25

Non-GAAP

Abbott
Reported

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

13,013

40

13,053

11,369

851

(23)

12,197

14.5

7.0

U.S.

5,504

—

5,504

4,299

824

(23)

5,100

28.0

7.9

Intl

7,509

40

7,549

7,070

27

—

7,097

6.2

6.4

Total Diagnostics

3,305

(2)

3,303

2,253

851

—

3,104

46.7

6.4

U.S.

1,853

—

1,853

886

824

—

1,710

109.2

8.4

Intl

1,452

(2)

1,450

1,367

27

—

1,394

6.2

4.0

Total Cancer Diagnostics

968

—

968

—

851

—

851

n/a

13.8

U.S.

938

—

938

—

824

—

824

n/a

13.9

Intl

30

—

30

—

27

—

27

n/a

12.1

Total Medical Devices

5,826

22

5,848

5,448

—

(23)

5,425

6.9

7.8

U.S.

2,687

—

2,687

2,521

—

(23)

2,498

6.6

7.6

Intl

3,139

22

3,161

2,927

—

—

2,927

7.2

8.0

Total Structural Heart*

592

4

596

580

—

(23)

557

1.9

6.9

U.S.

228

—

228

256

—

(23)

233

(11.1)

(2.3)

Intl

364

4

368

324

—

—

324

12.2

13.5

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Nine Months Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

9M26

9M25

% Change vs. 9M25

Non-GAAP

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

36,770

706

(8)

(460)

37,008

32,869

2,369

(69)

35,169

11.9

5.2

U.S.

14,994

681

(8)

—

15,667

12,743

2,294

(69)

14,968

17.7

4.7

Intl

21,776

25

—

(460)

21,341

20,126

75

—

20,201

8.2

5.7

Total Diagnostics

8,577

706

—

(100)

9,183

6,480

2,369

—

8,849

32.4

3.8

U.S.

4,418

681

—

—

5,099

2,568

2,294

—

4,862

72.0

4.9

Intl

4,159

25

—

(100)

4,084

3,912

75

—

3,987

6.3

2.4

Total Cancer Diagnostics

1,983

706

—

(1)

2,688

—

2,369

—

2,369

n/a

13.5

U.S.

1,921

681

—

—

2,602

—

2,294

—

2,294

n/a

13.5

Intl

62

25

—

(1)

86

—

75

—

75

n/a

15.0

Total Medical Devices

17,218

—

(8)

(284)

16,926

15,712

—

(69)

15,643

9.6

8.2

U.S.

7,890

—

(8)

—

7,882

7,363

—

(69)

7,294

7.1

8.1

Intl

9,328

—

—

(284)

9,044

8,349

—

—

8,349

11.7

8.3

Total Structural Heart*

1,767

—

(8)

(31)

1,728

1,692

—

(69)

1,623

4.4

6.5

U.S.

677

—

(8)

—

669

753

—

(69)

684

(10.2)

(2.3)

Intl

1,090

—

—

(31)

1,059

939

—

—

939

16.1

12.8

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          10

$             29

$         841

$           24

$        904

R&D

(7)

(5)

—

(16)

(28)

SG&A

(47)

(20)

—

(694)

(761)

Other (income) expense, net

(8)

(1)

—

13

4

Earnings before taxes

$           72

$             55

$         841

$          721

1,689

Taxes on Earnings (d)

132

Net Earnings

$      1,557

Diluted Earnings per Share

$        0.89

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$           —

$             44

$         420

$            6

$         470

R&D

—

(19)

—

(17)

(36)

SG&A

(9)

(43)

—

5

(47)

Other (income) expense, net

7

—

—

(2)

5

Earnings before taxes

$            2

$            106

$         420

$           20

548

Taxes on Earnings (d)

(86)

Net Earnings

$         634

Diluted Earnings per Share

$        0.36

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          44

$             40

$        1,921

$           28

$       2,033

R&D

(18)

(15)

—

(44)

(77)

SG&A

(533)

(54)

—

(1,075)

(1,662)

Other (income) expense, net

(9)

(4)

—

(17)

(30)

Earnings before taxes

$         604

$             113

$        1,921

$        1,164

3,802

Taxes on Earnings (d)

(62)

Net Earnings

$       3,864

Diluted Earnings per Share

$         2.21

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$            1

$            125

$       1,260

$           10

$       1,396

R&D

(1)

(42)

—

(40)

(83)

SG&A

(15)

(49)

—

6

(58)

Other (income) expense, net

(18)

—

—

(13)

(31)

Earnings before taxes

$           35

$            216

$       1,260

$           57

1,568

Taxes on Earnings (d)

(94)

Net Earnings

$       1,662

Diluted Earnings per Share

$        0.95

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

SOURCE Abbott

Abbott plans to separate its nutrition business into an independent company with about $8.5 billion in annual sales.

Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and Ensure Abbott will have accelerated sales growth and an expanded margin profile Abbott intends to separate its Nutrition business through a tax-free distribution to Abbott shareholders Separation expected to be completed by the end of 2027 , /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced its intention to separate its Nutrition business into an independent, publicly traded company that will be a global leader in the rapidly expanding healthy nutrition market with approximately $8.5 billion in annual sales and a portfolio of iconic brands.

"As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities. At the same time, Abbott's core higher-growth, innovation-driven portfolio of medical devices, diagnostics and established medicines has compelling growth opportunities to improve the health and lives of people around the world."

With different investment identities and requirements, growth profiles, and innovation cycles, both companies will benefit from resource and capital allocation strategies aligned to their distinct business models.

Nutrition: A leading healthy nutrition company
The Nutrition company will be a global leader in healthy nutrition with approximately $8.5 billion in annual sales. With about 16,000 employees and 14 manufacturing sites, it will have scale across developed and emerging markets and will be well positioned to capitalize on consumer health and nutrition trends, including metabolic health, prevention and wellness.

As an independent company, it will be better positioned to focus its resources more strategically across innovation, commercial activities and key initiatives that advance performance and long-term value creation.

Its portfolio of iconic global brands with leadership positions across infant, pediatric, medical and adult nutrition is highly differentiated in its competitive set and backed by evidence-based scientific research and healthcare professional recommendation, which drives durable organic growth at scale across channels. Abbott's Nutrition portfolio is anchored by category-leading brands, including Ensure, the world's No. 1 adult nutrition supplement drink; PediaSure, the world's No. 1 pediatric nutrition supplement; Glucerna, the world's No. 1 diabetes management nutrition brand; and Similac, the No. 1 infant formula brand in the U.S.

The Nutrition business has continued to innovate its portfolio – underpinned by consumer preferences and trends – with 10 product launches in the first half of 2026, including a high-protein Ensure shake featuring 42 grams of protein, the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. under the Similac brand, and dye-free Pedialyte products.

Daniel Salvadori, executive vice president and group president, Established Pharmaceuticals and Nutritional Products, will become chief executive officer of the new Nutrition company. Mr. Salvadori joined Abbott in 2014 and has successfully led complex international businesses, as senior vice president, Established Pharmaceuticals, Latin America and executive vice president of Nutritional Products before being appointed to his current position in 2021. Prior to Abbott, he held leadership roles at CFR Pharmaceuticals and Sandoz.

Abbott: A fast-growing global health leader
Abbott will remain one of the largest, fastest growing and most diversified healthcare companies with unique breadth and scale. After the transaction, Abbott will have sales of approximately $42 billion and market-leading positions in cardiovascular and neuromodulation devices; biowearables; laboratory, point-of-care and cancer diagnostics; and established medicines. Abbott's portfolio helps people manage a range of conditions and enable informed and earlier clinical decision making.

The company remains aligned with evolving and durable healthcare trends, including an aging population, growing prevalence of chronic disease, personalized treatment and greater demand for earlier diagnosis so people can stay and get healthy. Abbott will maintain a balanced portfolio of products and payors with a strong presence across both developed and emerging markets.

Transaction Details
Abbott intends to separate the Nutrition business through a distribution of shares of the independent Nutrition company to Abbott shareholders. Upon completion of the separation, Abbott shareholders will own shares in both Abbott and the independent Nutrition company.

Abbott expects the combined dividend to be paid by Abbott and the new Nutrition company to be equal to Abbott's dividend at the time of separation. The transaction is intended to qualify as a tax-free separation for U.S. federal income tax purposes.

Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10 and final approval by the Abbott Board of Directors.

The planned separation will not impact Abbott's guidance for 2026 or the guidance for 2027 that Abbott plans to provide in January. Abbott expects to incur one-time charges related to the transaction during the periods preceding the separation, to be quantified at a later date.

The Nutrition business will continue to operate as part of Abbott throughout the separation process.

Goldman Sachs & Co. LLC is serving as financial advisor to Abbott, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Abbott.

Abbott Conference Call
Abbott will discuss the transaction on its third-quarter earnings conference call today at 8 a.m. Central time (9 a.m. Eastern time). The webcast will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later today.

Frequently Asked Questions

Why is Abbott intending to separate its nutrition business?
Abbott has a successful history of shaping the company through internal and external actions that deliver on evolving growth opportunities.

We regularly examine the makeup of the company, and it is clear that the Nutrition business has a unique opportunity to capitalize on consumer preferences and trends in healthy nutrition. As an independent company, it will be better positioned to focus its resources more strategically across innovation, commercial activities and key initiatives that advance performance and long-term value creation. At the same time Abbott will focus on its core higher-growth, innovation-driven portfolio of medical devices, biowearables, diagnostics and established pharmaceuticals, which has compelling opportunities to expand health impact for people around the world.

With different investment identities and requirements, growth profiles and innovation cycles, both companies will benefit from resource and capital allocation strategies aligned to their distinct business models.

What will the profile of the new Nutrition company be after the separation?
The new Nutrition company will be a global leader in healthy nutrition with approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites. It will have a portfolio of household brands across infant, pediatric, medical and adult nutrition, including Similac, PediaSure, Pedialyte, Glucerna and Ensure. The new Nutrition company will be differentiated by its product offerings, which are backed by evidence-based scientific research and healthcare professional recommendation, as well as its presence and scale across both developed and fast-growing emerging markets.

What will Abbott look like after the separation? 
Abbott remains one of the largest, fastest growing and most diversified healthcare companies with unique breadth and scale. It will have sales of approximately $42 billion, about 106,000 employees and market-leading positions in cardiovascular and neuromodulation devices; biowearables; laboratory, point-of-care and cancer diagnostics; and established medicines. This portfolio helps people stay and get healthy, manage chronic conditions and enable informed and earlier clinical decision making.

When will the separation be complete?
Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10 and final approval by the Abbott Board of Directors.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements regarding the planned separation of the Nutrition business from Abbott and the expected financial results and prospects of Abbott and the new Nutrition company following the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Additional factors relating to the planned separation, including the ability to satisfy the conditions necessary to complete the transaction, obtain applicable regulatory approvals and tax rulings, successfully separate the businesses, and realize the expected benefits of the transaction, may also cause actual results to differ materially from those indicated in the forward-looking statements. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE Abbott

Abbott Laboratories (NYSE:ABT) will release its third quarter earnings report before the opening bell on Wednesday, Oct. 21.

Analysts on Wall Street project that Abbott (ABT - Free Report) will announce quarterly earnings of $1.42 per share in its forthcoming report, representing an increase of 9.2% year over year. Revenues are projected to reach $12.97 billion, increasing 14.1% from the same quarter last year.

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

Bearing this in mind, let's now explore the average estimates of specific Abbott metrics that are commonly monitored and projected by Wall Street analysts.

The collective assessment of analysts points to an estimated 'Net sales- Nutrition' of $2.21 billion. The estimate suggests a change of +2.7% year over year.

Analysts' assessment points toward 'Net sales- Diagnostics' reaching $3.29 billion. The estimate indicates a year-over-year change of +45.9%.

Based on the collective assessment of analysts, 'Net sales- Medical Devices- Diabetes Care' should arrive at $2.20 billion. The estimate indicates a year-over-year change of +6.8%.

According to the collective judgment of analysts, 'Net sales- Established Pharmaceuticals' should come in at $1.61 billion. The estimate points to a change of +6.8% from the year-ago quarter.

Analysts predict that the 'Net sales- Nutrition- U.S.' will reach $931.65 million. The estimate indicates a change of +4.9% from the prior-year quarter.

It is projected by analysts that the 'Net sales- Nutrition- International' will reach $1.28 billion. The estimate suggests a change of +1.3% year over year.

The combined assessment of analysts suggests that 'Net sales- Diagnostics- U.S.' will likely reach $1.85 billion. The estimate indicates a change of +108.3% from the prior-year quarter.

The consensus among analysts is that 'Net sales- Diagnostics- International' will reach $1.44 billion. The estimate suggests a change of +5.7% year over year.

Analysts expect 'Net sales- Medical Devices- Neuromodulation- International' to come in at $63.91 million. The estimate indicates a year-over-year change of +10.2%.

The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $388.69 million. The estimate indicates a year-over-year change of +11.1%.

The consensus estimate for 'Net sales- Medical Devices- Rhythm Management- International' stands at $350.76 million. The estimate indicates a change of +4.4% from the prior-year quarter.

Analysts forecast 'Net sales- Medical Devices- Structural Heart- U.S.' to reach $245.18 million. The estimate indicates a change of -17.5% from the prior-year quarter.

View all Key Company Metrics for Abbott here>>>

Abbott shares have witnessed a change of +2.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), ABT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Krilogy Financial LLC boosted its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 36.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,924 shares of the healthcare product maker’s stock after buying an additional 6,960 shares during the quarter. Krilogy Financial LLC’s holdings in Abbott Laboratories were worth $2,640,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ABT. BlackRock Inc. grew its stake in shares of Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp lifted its position in shares of Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. J. Stern & Co. LLP lifted its position in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Abbott Laboratories by 0.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock valued at $2,241,076,000 after purchasing an additional 118,014 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in Abbott Laboratories during the second quarter worth about $1,603,607,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Up 0.4% Shares of Abbott Laboratories stock opened at $103.04 on Thursday. The firm has a market cap of $178.29 billion, a PE ratio of 33.35, a P/E/G ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a fifty day moving average price of $106.03 and a 200-day moving average price of $98.26.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.26 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year. Abbott Laboratories Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Wall Street Analyst Weigh In A number of equities research analysts have issued reports on ABT shares. JPMorgan Chase & Co. upped their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. TD Cowen reissued a “buy” rating and set a $135.00 target price on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price on the stock. Citigroup boosted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, Wells Fargo & Company upped their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $118.88.

View Our Latest Analysis on ABT

Abbott Laboratories Company Profile (Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Read More Five stocks we like better than Abbott Laboratories Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

The stock market is flashing a warning sign. The Shiller CAPE Ratio is approaching 42, its second-highest reading in 150 years (hit right before the dot-com crash). However, instead of selling stocks and going into cash, I've been buying companies built to survive moments like these.

Three of my recent purchases were Abbott (ABT +0.89%), PepsiCo (PEP +0.13%), and Procter & Gamble (PG -0.17%). All three are Dividend Kings (companies with 50 or more years of annual dividend increases) and top holdings of the Schwab U.S. Dividend Equity ETF (SCHD +0.24%). Here's why I think they're ideal stocks to buy at a time when the market is historically overvalued.

Image source: Getty Images.

The warning signalThe Shiller CAPE ratio (cyclically adjusted price-to-earnings ratio) measures whether the stock market is overvalued or undervalued relative to its historical inflation-adjusted earnings record. It just hit its highest level since the dot-com era. That's a bad omen as the S&P 500 (^GSPC -0.01%) lost nearly half its value over the next two-and-a-half years.

Another notable peak came in Oct. 2021 when the Shiller CAPE ratio hit 38.6. That preceded the 2022 rate-driven bear market in stocks.

These three Kings stand outI'm not predicting that the stock market will crash. However, with the Federal Reserve recently hiking interest rates for the first time in three years, I'm becoming more defensive because stocks have historically declined during rate-hike cycles, as we saw in 2022. Still, I want to maintain upside in the equity market because it has historically recovered quickly following a Fed-induced decline.

That's why I'm adding some defensive ballast to my portfolio by investing in high-quality dividend stocks with durable revenues and strong balance sheets. Abbott, P&G, and PepsiCo all passed my quality screenings.

Premium Feature

Moneyball Superscore

76/100

Today's Change

(

0.89

%) $

0.91

Current Price

$

102.73

Abbott owns a diversified portfolio of high-quality healthcare products, including diagnostics, medical devices, nutritionals, and branded generic medicines. Demand for these products tends to be highly resilient and steadily rising. That's evident in its dividend, which Abbott has raised for 54 straight years. The company currently offers an attractive 2.5% yield and trades at a very reasonable 18.5x forward earnings (cheaper than the S&P 500's 19.5x forward earnings multiple). I think there's a clear case that Abbott's stock could more than double over the next decade, given its low valuation and solid earnings growth profile. It has the exact profile I'm seeking. A durable business, attractive and growing dividend, and compelling upside potential.

Procter & Gamble stood out for its collection of resilient household brands, which includes Bounty, Charmin, and Gillette. It's currently facing near-term pricing headwinds that have weighed on its valuation. As a result, it trades at less than 22 times forward earnings, near its lowest valuation over the past five years. That's why it currently offers a nearly 3% dividend yield. P&G has increased its dividend for 70 straight years, showcasing the durability of its business over the decades. I expect P&G to eventually get back to the mid-to-high single-digit annual core earnings growth rate it's targeting over the long term as its margins improve. Add in its strong cash flows and fortress balance sheet, and P&G offers ballast in a more turbulent market, with solid long-term upside potential.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

-0.17

%) $

-0.26

Current Price

$

152.94

Finally, PepsiCo also benefits from durable demand for its iconic portfolio of beverages and snacks. That has supported 54 years of dividend increases. Like P&G, it's currently facing headwinds that have weighed on its valuation (15x forward earnings). That's why it currently offers a dividend yield of more than 4.5%. That high starting yield provides a meaningful income return.

Meanwhile, PepsiCo doesn't need to grow very fast to deliver strong total returns. If the company can return to its long-term growth ambitions of high-single-digit core earnings-per-share growth, it could deliver double-digit total annual returns without any multiple expansion.

Premium Feature

Moneyball Superscore

71/100

Today's Change

(

0.13

%) $

0.17

Current Price

$

126.85

Independent validationI decided to add Abbott and P&G to my portfolio and increase my allocation to PepsiCo based on the individual merits of each company. However, I couldn't help but notice that they're all among the top holdings of the leading dividend-focused ETF, the Schwab U.S. Dividend Equity ETF. P&G is its third-largest holding (4.3% allocation), Abbott ranks 11th (3.8%), and Pepsi is 12th (3.8%).

The index this ETF tracks (Dow Jones U.S. Dividend 100 Index) screens dividend stocks based on several quality characteristics, including financial strength, dividend yield, and five-year dividend growth rate. Their high allocations in the fund show their relative strength among high-yielding dividend stocks. It's further evidence that they're high-quality holdings. As an investor in SCHD, I'm happy to increase my allocation to some of its top holdings, given its strong historical track record.

I'm taking the warning signs seriously but not panickingA historically high CAPE ratio, combined with a Fed rate hike cycle, is a reason to be cautious these days. That's why I'm adding more defensive ballast to my portfolio by investing in elite dividend stocks like Abbott, P&G, and PepsiCo. They should be less volatile if there's a market storm, while still delivering plenty of offensive upside.

Key Takeaways Abbott is expected to report Q3 EPS of $1.42, up 9.2%, and revenues of $12.91 billion, up 13.5%.ABT's Diagnostics revenues may surge 45.9%, led by cancer testing, Alinity platform growth and Exact Sciences.ABT shares gained 7.2% in Q3, while its forward P/E of 16.71X remains below its five-year median of 23.03X. Abbott Laboratories (ABT - Free Report) is slated to report its third-quarter 2026 results on Oct. 21, before the opening bell.

The Zacks Consensus Estimate for the company’s third-quarter earnings per share (EPS) suggests 9.2% year-over-year growth to $1.42. The estimate has remained constant in the past 60 days. The consensus mark for third-quarter revenues currently stands at $12.91 billion, implying a 13.5% increase over the prior-year period. 

Image Source: Zacks Investment Research

In the trailing four quarters, the company topped earnings estimates twice and broke even on two occasions, the average surprise being 0.81%.

Image Source: Zacks Investment Research

Q3 Earnings Whispers for AbbottPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.

Earnings ESP: Abbott has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks Rank #1 stocks here.

What May Have Influenced ABT’s Q3 Performance?DiagnosticsThebusiness is likely to have continued to seestrong and stable testing demand in the third quarter of 2026. Within this, Core Laboratory may have delivered another robust performance in the United States while extending its solid track record in Latin America, reflecting continued growth in diagnostic test sales on the Alinity platform. Rapid and Molecular Diagnostics results may improve following the end of a weaker-than-normal respiratory virus season in the second quarter.

Abbott’s acquisition of Exact Sciences has strengthened its position in cancer diagnostics and broadened its portfolio with products including Cologuard, Oncotype DX and Cancerguard. Cancer Diagnostics may have contributed to third-quarter sales growth, with Cologuard benefiting from a growing base of new and repeat users as well as growth in precision oncology and international markets.

The business may have also benefited from higher volumes through care gap programs, recently launched tests and continued international adoption, in line with management’s expectation of stronger growth in the second half of 2026 than in the first half.

The Zacks Consensus Estimate anticipates Diagnostics revenues to increase 45.9% year over year.

Established Pharmaceutical Products (“EPD”)Similar to the previous quarter, the segment is likely to have seen broad-based growth across the largest markets, including India, Latin America and Southeast Asia. Demand for health care in these emerging markets may have remained a key growth driver, supported by expanding access to care, aging populations and a rising need to treat both acute and chronic conditions. Abbott’s expanding biosimilars portfolio, which includes several leading oncology therapies, may have helped it meet growing demand across these markets and support revenues.

The Zacks Consensus Estimate suggests EPD revenues will grow 6.8% from the prior-period levels.

Medical DevicesAbbott’s cardiovascular businesses are expected to have accounted for the largest share of Medical Devices’ sales in the third quarter of 2026. Electrophysiology may have benefited from the transition of the Volt 2.0 PFA catheter to a full U.S. market release. Internationally, the continued rollout of Volt Pulsed Field Ablation and TactiFlex Duo Ablation Catheter, Sensor Enabled, may have continued to gain strong traction, aiding revenues. During the quarter, Abbott secured FDA approval for TactiFlex Duo and CE Mark approval of Amulet 360 Left Atrial Appendage (LAA) Occluder, which is intended for people with atrial fibrillation at risk of stroke.

In Rhythm Management, the continued expansion of AVEIR across single- and dual-chamber pacemaker segments may have supported revenues, alongside broader international adoption. Heart Failure performance in the United States is expected to have been driven by Abbott’s heart assist devices portfolio. Vascular sales may have benefited from growth in endovascular products.

The Diabetes Care business is likely to have maintained its growth momentum, led by continued growth in Abbott’s continuous glucose monitoring (CGM) systems in the United States and internationally. The company’s CE Mark approval for Libre Duo earlier this year may have also favored the quarter’s top line. The two-in-one biowearable provides real-time visibility into both glucose and ketone levels.

The Zacks Consensus Estimate expects Medical Devices revenues to increase 7.8% year over year.

NutritionIn the third quarter of 2026, the segment may have seen improving trends in both Pediatric and Adult Nutrition. International Pediatric Nutrition may have sustained its sales growth in the third quarter, having been the first of Abbott’s Nutrition businesses to return to positive growth. In the U.S. market, sales are likely to have continued to benefit from recent WIC contract wins.

Abbott may have also continued to see positive volume trends in Adult Nutrition following price actions implemented late last year. Product innovations, including new versions of Ensure featuring higher protein, lower sugar and refreshed labeling and packaging, may have supported the quarter’s sales. In August 2026, Abbott marked the U.S. launch of Similac360 Total Care Made With Whole Milk, the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk.

The Zacks Consensus Estimate indicates Nutrition revenues will rise 2.7% year over year.

ABT Peers: Upcoming ReleasesLabcorp Holdings (LH - Free Report) is set to report third-quarter 2026 results on Oct. 28, before the opening bell. Strength in both Diagnostics and Biopharma Laboratory Services businesses is expected to have supported performance. Labcorp has been making progress against its strategic priorities, including strengthening its specialty testing capabilities across oncology, neurology, autoimmune disease and women's health. Partnerships with health systems and regional and local laboratories are likely to support results by expanding access to Labcorp’s laboratory services, scientific expertise and broad testing portfolio, including specialty diagnostics.

Another close peer, Thermo Fisher (TMO - Free Report) , is slated to report its 2026 third-quarter results before the market opens on Oct. 21. Strength across the pharma and biotech end markets is expected to have supported performance, driven by bioproduction and clinical research businesses, as well as the research and safety market channel. Thermo Fisher’s strong cadence of high-impact innovations may have been a major boost to its revenues. Recent acquisitions, including Clario and Solventum’s filtration and separation business, are likely to support results as well.

ABT’s Price Performance & ValuationDuring third-quarter 2026, Abbott shares have risen 7.2% compared with a 0.7% gain for the industry.

Image Source: Zacks Investment Research

In terms of valuation, Abbott currently trades at a forward five-year Price/Earnings (P/E) of 16.71X, representing a slight premium to the industry average of 15.93X. However, the stock trades at a steep discount to its five-year median of 23.03X.

Image Source: Zacks Investment Research

EndnoteAbbott’s upcoming third-quarter results may reflect contributions from its diversified businesses, including Core Laboratory diagnostics, EPD products and Diabetes Care. Cancer Diagnostics sales may have benefited from increased Cologuard use, growth in precision oncology and continued international adoption. Improving demand and ongoing product innovation are likely to have supported the Nutrition business. In terms of share performance, Abbott outpaced the industry in the July-September quarter. The consensus outlook also points to year-over-year growth in earnings and revenues. With its current valuation below its historical average, ABT stock may offer an attractive entry point for prospective investors.

Abbott (ABT - Free Report) closed at $101.82 in the latest trading session, marking a +2.23% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Elsewhere, the Dow gained 0.38%, while the tech-heavy Nasdaq lost 0.44%.

Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 2.31% in the past month. In that same time, the Medical sector gained 0.04%, while the S&P 500 gained 2.36%.

Market participants will be closely following the financial results of Abbott in its upcoming release. The company plans to announce its earnings on October 21, 2026. The company's upcoming EPS is projected at $1.42, signifying a 9.23% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.91 billion, up 13.52% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.52 per share and revenue of $50.32 billion, indicating changes of +7.18% and +13.51%, respectively, compared to the previous year.

Investors should also pay attention to any latest changes in analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Abbott is currently a Zacks Rank #2 (Buy).

With respect to valuation, Abbott is currently being traded at a Forward P/E ratio of 18.04. Its industry sports an average Forward P/E of 19.61, so one might conclude that Abbott is trading at a discount comparatively.

One should further note that ABT currently holds a PEG ratio of 1.85. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry had an average PEG ratio of 1.74 as trading concluded yesterday.

The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 31% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Abbott (ABT +1.13%) currently trades for less than $100 a share. A conservative base-case model suggests the healthcare stock could be worth around $210 per share a decade from now. The best part is that doubling doesn't require anything close to optimistic assumptions; it's grounded in Abbott's recent history.

This high upside potential from a low-risk, high-quality dividend stock is why I just added Abbott to my portfolio this week.

Image source: The Motley Fool.

A history lessonIn 2016, Abbott generated nearly $21 billion in sales and $2.20 per share of adjusted earnings. This year, the healthcare company expects to report about $47 billion in sales and $5.53 of earnings at the mid-point of its current guidance range. That's a 9.7% compound annual earnings-per-share growth rate over the past decade.

Acquisitions helped Abbott deliver a nearly double-digit compound annual earnings growth rate over the past decade. In 2017, it bought both St. Jude Medical and Alere for $25 billion and $5.8 billion, respectively. These deals enhanced its operations and earnings (both were accretive in the first full year). The company also bought Exact Sciences earlier this year for $21 billion, a move that is boosting its 2026 results.

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

1.13

%) $

1.11

Current Price

$

99.60

Abbot's share price has followed its revenue and earnings higher. It's up 130% over the last 10 years (8.7% annualized total return). That doesn't include dividends. Add in Abbott's steadily rising dividend, and the total return with dividends reinvested is more than 175% (10.7% annualized). Abbott has increased its dividend for 54 consecutive years, qualifying it as a Dividend King (a company with 50 or more years of annual dividend increase).

The math to $210 (or more) by 2036I considered several scenarios when evaluating Abbott for my portfolio. I settled on a base case in which Abbott Labs grows its earnings at a 8% compound annual rate over the next decade. I chose that more conservative rate because acquisitions played a meaningful role in driving growth over the past 10 years. Under this conservative scenario, Abbott's earnings would grow to about $11.93 per share by 2036. Assuming a 17.5x valuation multiple (Abbott currently trades at about 18x forward earnings), that would put its share price at around $210.

That doesn't include Abbott's dividend, which currently yields 2.5%, more than double the S&P 500's level of around 1%. The company would likely continue to grow that payout at a mid-to-high single-digit annual rate (it hiked its dividend by 6.8% this year and has grown it by 70% since 2020).

Abbott fits perfectly with my current financial plan. I'm seeking more resilient, income-focused holdings to set me up for an early retirement if AI ever disrupts my job. Abbott checks every box. It provides durable, steadily rising dividend income backed by a diversified portfolio of healthcare technologies, including diagnostics, medical devices, nutritionals, and branded generic medicines. It's the exact type of defensive holding I'm seeking to provide more ballast.

Further, Abbott provides a strong defense without giving up any offensive upside. With a 2.5% dividend yield and earnings growing conservatively at 8% annually, Abbott could generate double-digit annual returns over the next 10 years. That strong return doesn't require any large acquisitions to boost its results. Meanwhile, faster acquisition-driven growth would position Abbott to generate even higher returns. For example, a 9%+ earnings growth rate with a slightly higher valuation multiple would push the stock price toward $250 by 2036.

I also like that the downside risk is low. The company does have risks, including integrating Exact Sciences and managing the heavier debt load from that all-cash deal. However, even if growth slowed and its valuation multiple continued to fall, Abbott should still be worth more in a decade than it is today while also providing a steadily rising income stream.

Abbott's history says it has a bright futureAbbott has historically grown its earnings at a nearly 10% compound annual rate over the last decade. It doesn't need to grow that fast in the future to deliver a very favorable outcome for shareholders, as 8% annual earnings-per-share growth could double its share price by 2036, with its steadily rising, high-yielding dividend adding to the total return. That's exactly the lower-risk, higher-upside investment I'm seeking to make these days, which is why I just added Abbott to my portfolio. I expect to build this position into a meaningful part of my financial independence plan.

An updated edition of the August 26, 2026, article.

The global oncology market is evolving rapidly, fueled by rising cancer incidence, aging populations and continued medical advances. According to the American Cancer Society, the United States is projected to record nearly 2.1 million new cancer cases and more than 626,000 cancer deaths in 2026. Worldwide, demographic shifts and risk factors such as smoking, obesity and physical inactivity are contributing to the growing cancer burden and increasing demand for treatments.

Meanwhile, advances in medical science are transforming cancer care. Immunotherapies, targeted medicines and personalized cancer vaccines are expanding treatment options beyond conventional chemotherapy and radiation. Approaches such as checkpoint inhibitors, CAR-T therapies, therapeutic vaccines and oncolytic viruses offer new ways to fight cancer. Targeted drugs address specific genetic or molecular changes, while personalized vaccines aim to tailor treatment to individual patients.

Genomic sequencing, artificial intelligence and machine learning are also improving biomarker identification, patient selection and diagnostic precision. While a universal cure remains elusive, advances in screening, early detection and treatment are helping improve survival and patient outcomes across several cancer types.

Pharmaceutical companies are making oncology a key growth priority, investing heavily in R&D and expanding their pipelines. Industry leaders such as Novartis (NVS - Free Report) , AstraZeneca (AZN - Free Report) , J&J (JNJ - Free Report) , Pfizer (PFE - Free Report) , AbbVie (ABBV - Free Report) , Merck, Bristol Myers Squibb and Eli Lilly are developing innovative treatments, including antibody-drug conjugates (ADCs), bispecific antibodies and next-generation immunotherapies. Smaller biotech companies are also contributing to innovation, with their novel targets and technologies attracting partnerships, licensing deals and acquisition interest.

Ongoing scientific advances, unmet medical needs and an expanding range of treatment options make oncology an important long-term growth area for the healthcare industry, creating potential opportunities for pharmaceutical companies and investors.

With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. For those looking to gain exposure to the oncology space, companies such as Pfizer, Merit Medical Systems (MMSI - Free Report) and Abbott Laboratories (ABT - Free Report) may be worth evaluating as part of a forward-looking portfolio strategy.

Explore 40 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.

3 Cancer Stocks in FocusPfizer is one of the world’s leading oncology drugmakers with a broad portfolio of marketed cancer therapies as well as a deep oncology pipeline spanning multiple treatment modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.

Oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 5% in the first half of 2026, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer considers Padcev to be a potential growth driver in the oncology segment and plans to invest in this asset.

Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. It is also advancing its oncology clinical pipeline across areas such as breast, thoracic, gastrointestinal and blood cancers. Several oncology candidates have entered late-stage development, such as atirmociclib (a selective CDK4 inhibitor for HR-positive/HER2-negative breast cancer), sigvotatug vedotin (an antibody-drug conjugate for first-line metastatic non-small cell lung cancer) and mevrometostat (an EZH2 inhibitor being developed in combination with enzalutamide for prostate cancer).

A key candidate in its oncology pipeline is PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025. Pfizer has initiated nine studies, including two pivotal phase III studies for PF-08634404 in first-line metastatic colorectal cancer and first-line NSCLC. Pfizer aims to establish PF-08634404 as a potential backbone therapy across multiple tumor types. By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio.

Pfizer has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Merit Medical Systems’ oncology business is becoming an increasingly important part of its Therapeutic portfolio, although it is still relatively small compared with the company’s overall revenue base.

Merit Medical Systems’ oncology portfolio includes SCOUT and SCOUT MD for wire-free tumor localization, OneMark for lesion marking during breast biopsies, soft-tissue biopsy devices, SAVI for partial-breast brachytherapy, and interventional oncology products such as Embosphere and HepaSphere microspheres.

Its oncology revenues grew 7% to $49.3 million in the first half of 2026. The launch of SCOUT MD and the addition of the OneMark system from the April 2026 acquisition of View Point Medical have significantly expanded the addressable market for Merit’s oncology products.

Management estimates the U.S. oncology opportunity to increase from about 400,000 to 1.3 million procedures annually, supporting potentially stronger oncology growth over the next few years.

MMSI has a Zacks Rank #2.

Abbott has expanded its cancer portfolio significantly through its acquisition of Exact Sciences, a cancer diagnostics company, in March 2026, adding cancer screening, precision oncology and disease-monitoring tests to its existing diagnostic products and oncology biosimilars. Its key cancer diagnostics include Cologuard, a noninvasive stool-based test for colorectal cancer screening; Cancerguard, a blood-based multi-cancer early-detection test designed to screen for signals of more than 50 cancer types; Oncotype DX, which helps guide treatment decisions for patients with certain early-stage breast cancers and colon cancer by assessing recurrence risk and potential treatment benefit; and Oncodetect, a tumor-informed molecular residual disease (MRD) test that detects traces of cancer DNA to help monitor recurrence.

Abbott also offers hereditary cancer testing through Riskguard. In addition, its international pharmaceutical business includes oncology biosimilars and biologic treatments, such as bevacizumab and trastuzumab biosimilars, used for certain solid tumors.

Cancer diagnostics sales grew 13% to $919 million in the second quarter of 2026, supported by Cologuard and precision oncology.

Abbott's key cancer pipeline opportunities are next-generation blood-based colorectal cancer tests, improved MRD testing platforms to detect cancer recurrence, and screening technologies targeting cancers such as liver cancer, for which routine screening options remain limited.

Abbott has a Zacks Rank of 2.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT - Free Report) .

Abbott currently has an average brokerage recommendation (ABR) of 1.41, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.41 approximates between Strong Buy and Buy.

Of the 29 recommendations that derive the current ABR, 22 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 75.9% and 6.9% of all recommendations.

Brokerage Recommendation Trends for ABT

Check price target & stock forecast for Abbott here>>>

While the ABR calls for buying Abbott, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in ABT?Looking at the earnings estimate revisions for Abbott, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.52.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abbott. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Abbott.

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preserve muscle Ensure Max Protein 3-in-1 formula provides muscle support in a single daily serving to support muscle health goals—and is available in chocolate and vanilla at major U.S. retailers Muscle-supporting ingredients like creatine and HMB are moving beyond the gym and into mainstream wellness routines as more adults prioritize strength and fitness , /PRNewswire/ -- Muscle support just got simpler. Abbott (NYSE: ABT) today announced the launch of Ensure Max Protein 3-in-1 Muscle Support, a protein powder that combines three key ingredients in one product: protein to help build muscle tissue,† creatine to support exercise recovery‡* and HMB to help preserve muscle.

Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop Once associated primarily with athletes and bodybuilders, muscle health is gaining wider appeal as a cornerstone of longevity. As more consumers embrace strength training and seek nutritional support to stay active, many find themselves piecing together multiple products to support their muscle health goals. Abbott helps to simplify the supplement "stack" with Ensure Max Protein 3-in-1 Muscle Support, bringing three science-backed ingredients together in one convenient powder.

"People are thinking about muscle health differently. It's not just about lifting weights—it's about having the strength to embrace an active lifestyle, achieve personal goals and make the most of everyday moments," said Bridget Cassady, PhD, RDN, LD, dietitian with Abbott. "That's why we're going beyond protein to add creatine and HMB to our new Ensure Max Protein 3-in-1 Muscle Support, which brings these science-backed ingredients together in one simple solution."

Meeting the growing interest in muscle health
The growing interest in muscle health and overall strength has fueled awareness of ingredients such as creatine, which are breaking out of the gym and into some unexpected spaces. According to estimates, the global creatine market is projected to reach $4.2 billion by 2030. Researchers are also expanding their focus on creatine beyond athletic performance, investigating its potential role in areas including women's health, cognition and muscle mass and strength in older adults. 

To meet this evolving consumer need, Abbott developed Ensure Max Protein 3‑in‑1 Muscle Support, combining three key ingredients with distinct muscle-supporting benefits:

30 grams of protein: The high-quality protein in Ensure Max Protein 3-in-1 Muscle Support delivers all the essential amino acids to help build muscle tissue when combined with resistance training* 5 grams of creatine monohydrate: Creatine is a compound that is naturally found in foods like meat and fish and produced by the body. Ensure Max Protein 3-in-1 contains creatine monohydrate, one of the most studied forms of the ingredient, to help support muscle strength and power† as well as exercise recovery from and during high-intensity exercise* 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate): HMB is derived from an amino acid, but it is difficult to obtain meaningful amounts through diet alone. Ensure Max Protein 3-in-1 Muscle Support contains the studied amount of calcium HMB shown to help preserve muscle tissue by slowing protein breakdown1, 2*   Available in chocolate and vanilla, Ensure Max Protein 3-in-1 Muscle Support is sold at Walmart and Amazon. This product comes in a 28-ounce powder format with a suggested serving of two scoops mixed with 12 fluid ounces of liquid once daily or added to smoothies, yogurt and oatmeal.

Advancing nutrition for muscle health
The launch reflects both the evolving needs of consumers and Abbott's vision for the future of muscle health: nutrition solutions designed to support both short-term performance goals and long-term health.

Ensure Max Protein 3-in-1 Muscle Support combines protein, creatine and HMB in amounts supported by research and is third-party NSF Contents Certified, providing added assurance around quality, purity and label transparency. By bringing these ingredients together in one convenient daily serving, Abbott is making effective muscle health nutrition easier to incorporate into everyday life.

To learn more, visit Ensure.com and follow @Ensure on Instagram and Facebook.

Frequently Asked Questions:
What is Ensure Max 3-in-1 Muscle Support?
Ensure Max Protein 3-in-1 Muscle Support is a protein powder that combines three key ingredients in one product: 30 grams of protein to help build muscle tissue,† 5 grams of creatine monohydrate to support exercise recovery‡* and 3 grams of calcium HMB to help preserve muscle. This product comes in a 28-ounce powder format with a suggested serving of two scoops mixed with 12 fluid ounces of liquid once daily.

What does creatine do for exercise performance?
In the context of exercise, creatine helps support performance during activities like lifting, sprinting or other high-intensity training. By helping your muscles maintain energy, it can support the quality of your workouts and help with exercise recovery, both between sets and after more intense sessions, so your muscles are better prepared for your next workout.*

Is creatine safe for adults?
Yes, creatine monohydrate is one of the most studied sports nutrition ingredients and is safe for active adults when used as directed, including long-term. As with any dietary supplement, individuals with underlying medical conditions or who are pregnant or nursing should consult a healthcare professional before use.

Can people taking GLP-1 medications use Ensure Max Protein 3-in-1 Muscle Support?
Ensure Max Protein 3-in-1 Muscle Support provides 30 grams of high-quality protein to help support muscle health, and research shows that adequate protein intake can help preserve muscle mass during intentional weight loss3. Individuals taking GLP-1 medications should consult a healthcare professional before using the product to determine whether it is appropriate for their individual nutritional needs, medication regimen, and medical history.

Why is Ensure Max Protein 3-in-1 Muscle Support only available in a powdered format?
Creatine works best in a dry powder format. When pre-mixed in liquids for extended periods, it can break down into creatinine, a natural byproduct that the body eliminates, and it may also clump over time. Because consumers are already accustomed to using protein and creatine powders, Abbott developed Ensure Max Protein 3-in-1 Muscle Support in a convenient powder format.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

1 Wilkinson DJ, et al. J Physiol. 2013;591(11):2911-2923.
2 Wilkinson DJ, et al. Clin Nutr. 2018;37(6 Pt A):2068-2075.
3 Kokura Y, et al. Clin Nutr ESPEN. 2024;63:417-426. doi:10.1016/j.clnesp.2024.06.030. PMID:39002131.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
† When combined with resistance training. 
‡ From and during high-intensity exercise.

SOURCE Abbott

Park National Corp OH lessened its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 6.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,913 shares of the healthcare product maker’s stock after selling 10,269 shares during the period. Park National Corp OH’s holdings in Abbott Laboratories were worth $13,828,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. grew its stake in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp grew its position in Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Capital International Investors lifted its position in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP grew its holdings in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its position in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after acquiring an additional 400,400 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance Abbott Laboratories stock traded up $2.63 during mid-day trading on Monday, hitting $100.13. 3,498,474 shares of the company’s stock traded hands, compared to its average volume of 11,315,676. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a 50 day simple moving average of $106.99 and a two-hundred day simple moving average of $98.60. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.24. The stock has a market cap of $173.27 billion, a price-to-earnings ratio of 32.45, a P/E/G ratio of 1.81 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Analyst Ratings Changes Several research analysts recently commented on ABT shares. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. BTIG Research increased their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Finally, Citigroup boosted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $119.80.

View Our Latest Stock Analysis on Abbott Laboratories

(Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Featured Articles Five stocks we like better than Abbott Laboratories A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You?

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits , /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones, giving them greater insight into their condition and helping them take a more active role in their care.

Heart failure can worsen long before symptoms become noticeable. Pulmonary artery pressure — the pressure of blood flowing from the heart to the lungs — can rise as heart failure worsens, often weeks before patients experience any symptoms. The CardioMEMS HF System, which has been shown to reduce heart failure hospitalizations2,3 and mortality risk4,5, measures pulmonary artery pressure through an implanted sensor in the pulmonary artery. For more than a decade, clinicians have used pulmonary artery pressure readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment.

Building on that clinical experience with CardioMEMS, Abbott is continuing to evolve heart failure management with digital tools that help keep clinicians and patients connected between office visits. The CardioMEMS HF System with the CardioGuide HF App represents an important step toward helping patients take an earlier, more active role in understanding and managing their heart failure.

"Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop," said Andrew J. Sauer, M.D., cardiologist and vice president for research at Saint Luke's Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City. "By giving patients access to their pressure trends and personalized guidance from their care team, the CardioGuide HF App can help patients better understand their condition, understand why treatment adjustments are recommended, and take a more active role in managing their heart failure."

The new CardioMEMS HF System capabilities also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure. Once in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App, ensuring patients receive timely feedback and guidance from their care team.

"Abbott is reshaping heart failure care by bringing meaningful, actionable information directly to patients," said Katie Spayde, vice president of Abbott's heart failure division. "For many people living with heart failure, managing their condition is part of everyday life. By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits."

Abbott plans to make CardioGuide HF App and Dynamic Treatment Plan available later this year.

Frequently Asked Questions

What is heart failure?
Heart failure is a chronic, progressive condition in which the heart is unable to pump enough blood to meet the body's needs. It can cause shortness of breath, fatigue and swelling, and tends to worsen over time. Heart failure affects millions of people worldwide and is a leading cause of hospitalization.

What is pulmonary artery pressure, and why does it matter in heart failure?
Pulmonary artery pressure is the pressure of blood flowing from the right side of the heart into the lungs. Rising pulmonary artery pressure is one of the earliest signs of worsening heart failure, often before a patient feels any symptoms. Monitoring pulmonary artery pressure remotely helps clinicians detect these changes early and adjust treatment before hospitalization is needed.

What is the CardioGuide HF App?
The CardioGuide HF App is a mobile app for people living with heart failure who have a CardioMEMS pulmonary artery pressure sensor. The app displays a patient's own pulmonary artery pressure readings and trends on their iOS or Android smartphone.

How does the CardioGuide HF App work with the CardioMEMS HF System?
The CardioMEMS HF System includes an implanted pulmonary artery pressure sensor, the CardioMEMS HERO device and the Merlin.net Patient Care Network Portal.

Individuals implanted with a CardioMEMS sensor can use the CardioMEMS HERO device to take pressure readings, which are transmitted to their care team through the Merlin.net Patient Care Network Portal. The CardioGuide HF App complements the system by giving patients direct visibility into their pulmonary artery pressure readings and trends on their smartphones.

Together, the CardioMEMS HF System and CardioGuide HF App help keep both clinicians and patients informed and engaged in heart failure management.

What is the Dynamic Treatment Plan?
Dynamic Treatment Plan (DTP) is a feature available through Abbott's Merlin.net Patient Care Network Portal that enables care teams to communicate treatment plan updates directly to CardioMEMS patients through the CardioGuide HF App. When enabled by a clinician, patients can receive updates related to their individual heart failure management plan through the CardioGuide HF App.

About the CardioMEMS HF System
Abbott's CardioMEMS HF System is the leading remote hemodynamic monitoring platform for heart failure patients. The system features a small pressure-sensing device implanted permanently in the pulmonary artery. The device allows clinicians to remotely monitor pulmonary artery pressure through the Merlin.net Patient Care Network Portal and proactively adjust treatment before hospitalization is needed. Supported by more than a decade of clinical evidence, CardioMEMS is the most-studied1 and only FDA-approved wireless heart failure monitoring system proven to reduce heart failure hospitalizations2,3 and mortality risk4,5. Additional information about the CardioMEMS HF System is available here.

Indications and Important Safety Information
For U.S. important safety information on the CardioMEMS HF System, visit: Indications, Safety and Warnings for the CardioMEMS HF System.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube. 

1Abbott. Data on file.
2Heywood JT, Zalawadiya S, Bourge RC, et al. Sustained reduction in pulmonary artery pressures and hospitalizations during 2 years of ambulatory monitoring. J Card Fail. 2023;29(1):56–66. doi: 10.1016/j.cardfail.2022.10.422.
3Adamson PB, Abraham WT, Stevenson LW, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circ Heart Fail. 2016;9(6):e002600. doi:10.1161/CIRCHEARTFAILURE.115.002600.
4Lindenfeld J, Costanzo MR, Zile MR, et al., on behalf of the GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators. Meta-Analysis of Implantable Hemodynamic Monitors for HFrEF. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2024;83:682-694. doi:10.1016/j.jacc.2023.11.030.
5Zalawadiya S, Abraham J, Rathman L, et al. Early reduction of pulmonary artery pressures is associated with improved mortality among Medicare beneficiaries with heart failure. JACC Heart Fail. 2025;13(10):102589. doi:10.1016/j.jchf.2025.102589.

SOURCE Abbott

As healthcare costs and procedure volumes continue to shift globally, investors must decide between two titans of the industry. Choosing between Abbott Laboratories (ABT -1.35%) and Intuitive Surgical (ISRG -1.12%) requires weighing diversified stability against high-growth specialized technology.

Abbott provides a broad array of medical products used in daily care, while Intuitive focuses on the specialized niche of robotic-assisted surgery. These companies are often compared because they represent different ways to invest in the future of medical technology and hospital spending.

The case for Abbott LaboratoriesAbbott Laboratories operates a diversified business model that spans diabetes care, cardiovascular devices, diagnostics, and nutrition. It sells products to a wide range of customers, including hospitals, wholesalers, and government agencies, which helps it weather fluctuations in any single market. In early 2026, the company entered a definitive agreement to acquire Exact Sciences to strengthen its presence in the cancer diagnostics market.

In FY 2025, revenue reached nearly $44.3 billion, representing a growth of roughly 5.7% compared to the previous year. The company reported net income of approximately $6.5 billion for the period, resulting in a net margin of close to 14.7%. This performance reflects steady demand across its various healthcare segments, particularly in its medical device and diagnostic divisions.

Abbott maintains a stable financial position with a debt-to-equity ratio of nearly 0.3x as of its December 2025 balance sheet. This ratio, which compares total debt to shareholder equity, suggests a conservative approach to borrowing. The company also reported a current ratio of roughly 1.6x, indicating it has enough short-term assets to cover its immediate liabilities. Free cash flow, or the cash left after paying for operating costs and capital expenditures, reached approximately $7.4 billion in FY 2025.

The case for Intuitive SurgicalIntuitive Surgical is the pioneer of robotic-assisted surgery, primarily through its da Vinci and Ion systems. The company operates a "razor and blade" business model, where the initial sale of a robotic system leads to years of recurring revenue from instruments, accessories, and maintenance services. Its primary customers are hospitals and ambulatory surgery centers, and it has recently expanded its direct sales reach into several European markets to improve its medical device stocks presence.

In FY 2025, revenue reached roughly $10.1 billion, which was a significant increase of approximately 20.5% over the prior year. Net income for the same period was close to $2.9 billion, yielding a strong net margin of nearly 28.4%. This robust profitability is driven by the high volume of surgical procedures performed using its installed base of robots worldwide.

As of its December 2025 balance sheet, the company has a debt-to-equity ratio of 0.0x, indicating that shareholder equity far exceeds its total debt. Its current ratio stands at approximately 4.9x, showing a very high level of liquidity to meet short-term obligations. Free cash flow for FY 2025 was nearly $2.5 billion. Note that stock-based compensation represented roughly 26% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement.

Risk profile comparisonAbbott Laboratories faces risks related to its complex manufacturing and supply chain, particularly its reliance on single-source suppliers for certain products. The company is also dealing with significant ongoing litigation involving product liability claims for infant formula and potential False Claims Act allegations. Intense competition from rivals like Medtronic (MDT +0.37%) and Johnson & Johnson (NYSE:JNJ) means Abbott must constantly innovate to protect its market share in the medical device and diagnostics sectors.

Intuitive Surgical faces competition from alternative surgical approaches and new robotic entrants like Medtronic and SS Innovations International (SSII -6.71%). Macroeconomic pressures could lead hospitals to tighten their capital spending budgets, potentially delaying the purchase of expensive new robotic systems. Additionally, the company is vulnerable to supply chain issues involving rare earth elements and must navigate increasingly strict global regulations regarding AI-enabled medical devices and patient data privacy.

Valuation comparisonAbbott Laboratories appears to be the more conservatively priced option, while Intuitive Surgical carries a higher premium due to its faster revenue growth.

MetricAbbott LaboratoriesIntuitive SurgicalForward P/E18.5x37.2xP/S ratio3.8x12.9xValuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

The Forward P/E ratio compares the current stock price to future earnings estimates, while the P/S ratio measures the market value against sales over the past twelve months.

I'd go with Intuitive Surgical. Its installed base of nearly 12,000 da Vinci surgical systems is a major, durable competitive advantage in healthcare. Once a hospital has trained its surgeons on the platform and built its workflows around it, switching is rarely worth the disruption. Recurring revenue accounts for roughly 85% of total revenue, procedures grew at a strong double-digit rate in the most recent quarter, and the company beat earnings estimates by a wide margin while raising its gross margin outlook.

Abbott Laboratories deserves credit for running a well-diversified healthcare business across medical devices, diagnostics, and nutrition, and its acquisition of Exact Sciences adds a more exciting diagnostics story. For investors who want broad healthcare exposure alongside a growing dividend, it is a solid choice.

But Intuitive is growing faster, with a more focused business and a platform that keeps deepening its relationships with every hospital that adopts it. For a patient investor, that compounding advantage is worth owning.

Abbott (ABT - Free Report) closed the most recent trading day at $98.83, moving -2.1% from the previous trading session. This change lagged the S&P 500's 0.25% loss on the day. On the other hand, the Dow registered a loss of 0.86%, and the technology-centric Nasdaq increased by 0.24%.

The stock of maker of infant formula, medical devices and drugs has fallen by 7.33% in the past month, lagging the Medical sector's loss of 1.01% and the S&P 500's loss of 0.42%.

The upcoming earnings release of Abbott will be of great interest to investors. In that report, analysts expect Abbott to post earnings of $1.43 per share. This would mark year-over-year growth of 10%. Meanwhile, the latest consensus estimate predicts the revenue to be $12.91 billion, indicating a 13.52% increase compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $5.52 per share and revenue of $50.32 billion, which would represent changes of +7.18% and +13.51%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Abbott presently features a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 18.28 right now. This signifies a discount in comparison to the average Forward P/E of 19.93 for its industry.

It's also important to note that ABT currently trades at a PEG ratio of 1.87. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABT's industry had an average PEG ratio of 1.76 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 101, this industry ranks in the top 42% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST - Free Report) and Abbott (ABT - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Envista and Abbott are both sporting a Zacks Rank of #2 (Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is only part of the picture for value investors.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

NVST currently has a forward P/E ratio of 15.72, while ABT has a forward P/E of 18.30. We also note that NVST has a PEG ratio of 1.15. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABT currently has a PEG ratio of 1.87.

Another notable valuation metric for NVST is its P/B ratio of 1.27. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ABT has a P/B of 3.38.

These metrics, and several others, help NVST earn a Value grade of A, while ABT has been given a Value grade of C.

Both NVST and ABT are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that NVST is the superior value option right now.

Envestnet Asset Management Inc. trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 23.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,956,395 shares of the healthcare product maker’s stock after selling 1,228,773 shares during the period. Envestnet Asset Management Inc. owned 0.23% of Abbott Laboratories worth $359,003,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock worth $7,343,246,000 after acquiring an additional 1,350,766 shares during the period. Premier Financial Group bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $118,000. Security National Bank of Sioux City Iowa IA lifted its holdings in Abbott Laboratories by 34.9% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 24,246 shares of the healthcare product maker’s stock worth $2,200,000 after purchasing an additional 6,268 shares in the last quarter. Menlo Advisors LLC boosted its stake in Abbott Laboratories by 1.1% in the 2nd quarter. Menlo Advisors LLC now owns 67,919 shares of the healthcare product maker’s stock worth $6,162,000 after purchasing an additional 723 shares during the period. Finally, Core Capital Management & Research inc. bought a new stake in shares of Abbott Laboratories during the second quarter valued at about $64,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Down 0.1% Shares of ABT opened at $103.62 on Thursday. The firm’s 50 day simple moving average is $107.15 and its 200 day simple moving average is $99.10. The company has a market capitalization of $179.31 billion, a P/E ratio of 33.53, a P/E/G ratio of 1.92 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $136.83.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year. Abbott Laboratories Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s payout ratio is 81.55%.

More Abbott Laboratories News Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott and Berry Street announced an exclusive partnership combining Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered registered-dietitian and nutrition-coaching platform. The initiative could improve Lingo adoption, expand Abbott’s consumer health ecosystem and strengthen its position in metabolic-health services. Abbott and Berry Street partnership article Positive Sentiment: Abbott’s Volt Pulsed Field Ablation System reportedly saw its first clinical use in Canada and at an Illinois heart center for treating atrial fibrillation. Additional real-world use could support the medical-device pipeline and future cardiovascular revenue growth. Abbott digital health and formula settlement article Positive Sentiment: Investor commentary continues to describe Abbott as a high-quality, diversified healthcare business with attractive long-term prospects. Its exposure to diagnostics, medical devices, nutrition and digital health provides multiple growth avenues, and the therapeutic drug-monitoring market is projected to expand substantially through 2032. What makes Abbott attractive article Neutral Sentiment: ABT is drawing increased attention from investors and analysts. Recent results exceeded consensus estimates, with revenue growth supported by the company’s diversified portfolio, but commentary generally characterizes the shares as a strong business available at a fair—not deeply discounted—price. Abbott trending stock article Negative Sentiment: Abbott agreed to pay approximately $385 million to settle infant-formula litigation. Although the settlement removes some legal uncertainty, the cash cost and reputational overhang are negative for near-term sentiment. Valuation comparisons with faster-growing healthcare companies, including Exact Sciences, may also reduce enthusiasm among growth-oriented investors. Abbott and Exact Sciences comparison article Analyst Upgrades and Downgrades A number of research firms have recently commented on ABT. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, TD Cowen reiterated a “buy” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

View Our Latest Report on Abbott Laboratories

Abbott Laboratories Profile (Free Report)

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Further Reading Five stocks we like better than Abbott Laboratories Chips to Bots: Qualcomm’s Agentic AI Breakout Ciena Fell 40%—Now One Analyst Sees 50% Upside Energy Transfer Taps the AI Power Boom Viking’s Obesity Edge May Be Staying Power, Not Weight Loss Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.